GlaxoSmithKline Plc said it failed
to win approval from U.S. regulators for expanded use of its
enlarged-prostate therapy Avodart to treat the estimated 1
million American men at risk for prostate cancer.
Glaxo received a so-called complete response letter from
the U.S. Food and Drug Administration rejecting the application
to expand Avodart’s use, the London-based company said today in
a statement. An FDA advisory panel voted 14-2
No comments:
Post a Comment